The neuroprotective effects of xenon on neonatal rats with white matter damage by regulating expression of microRNA-210 and HIF-1α

xiangyun yin
The Affiliated Hospital of Qingdao University

Jixiu Zhao
Jining First People's Hospital

Jian Jiang
The Affiliated Hospital of Qingdao University

Hongmin Xi
The Affiliated Hospital of Qingdao University

Xianghong Li
The Affiliated Hospital of Qingdao University

Lulu Zhang
The Affiliated Hospital of Qingdao University

Hong Jiang (jianghongbs@163.com)

Research article

Keywords: premature birth, Xenon, microRNA-210, HIF-1α, white matter damage

Posted Date: October 9th, 2019

DOI: https://doi.org/10.21203/rs.2.10732/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: White matter damage is a leading cause of acute mortality and chronic morbidity in preterm birth. Xenon is a general anesthetic with neuroprotective effects. We aimed to reveal the molecular basis and neuroprotective mechanism of Xe intervention in treating white matter damage by detecting the expression level of miR-210 and HIF-1α in brain tissues of 3-day-old neonatal rats. Methods: Three-day-old SD rats were randomly divided into sham group (Group A, n=24), LPS +HI group (Group B, n=24) and LPS+HI+Xe group (n=72). LPS+HI+Xe group was given Xenon gas inhalation for three hours after treatment of HI at 0h,2h, and 5h, and divided into three subgroups C,D, and E randomly. We investigated the WMD by performing TUNEL and hematoxylin and eosin (HE) staining and examining the expression of miR-210 and HIF-1α in brain tissues via RT-PCR and western blot. Results: Our study shows that the brain tissues of neonatal rat which stained by HE were pale, structure loosen, and psychosis along with apoptosis in group B, Xe treatment improved histological alterations and decreased the number of apoptotic cells in group C. The expression level of miR-210 increased significantly at all time points in group B compared to group A (p<0.05), while that was significantly lower at 0h and 48h than that of group C (p<0.05). Compared with group C, the expression of miR-210 in group D and group E decreased significantly at 0h, 24h and 48h (p<0.05). The level of HIF-1α protein in group B was significantly higher than that of group A at each time point, while significantly lower than that of group C at each time point and that of group D and E at 0h, 24h and 72h (p<0.05). Compared with group C and group D, the expression level of HIF-1α protein decreased significantly at 24h in group E (p<0.05). Conclusions: These results demonstrate that the expression of HIF-1α and miR-210 increased in periventricular tissues and Xe could relieve the white matter damage by up-regulating the expression of HIF-1α and its target gene miR-210. The Xe therapeutic time window was within 5 hours after intervention, the sooner the better. Keywords: premature birth, Xenon, microRNA-210, HIF-1α, white matter damage

Background

WMD is a prominent neurological deficit observed in preterm birth. WMD is a leading cause of acute mortality and chronic morbidity. [1] In a large cohort study, Hintz et al. previously reported that 19.3% of the surviving preterm infants developed cerebella lesions. [2] The pathogenesis of WMD in premature birth primarily involves cerebral hypoxia-ischemia injury, systemic inflammation and maternal or fetal infection. [3, 4] To date, there are no available pharmacological agents that can efficiently attenuate the premature WMD, promote recovery or minimize the severity of disability.

Xe is a noble gas used in general anesthesia. [5] Xenon possesses organ-protective effects in the brain. [6, 7] Moreover, xenon exhibited neuroprotective activity for the treatment of ischemic brain injury in combination with mild hypothermia in animal models. [8-11] Xenon is known to cross the blood-brain barrier (BBB) and has a low blood/gas solubility, which will reduce the risk of developing adverse effects. [12-14] Previous reports demonstrated that the anesthetic effect of xenon was primarily mediated through the inhibition of N-methyl-D-aspartate (NMDA) receptor. [15, 16] Particularly, Ma et al. demonstrated that xenon could induce the activation of hypoxia-inducible HIF-1α and provide preconditioning effects on
ischemic renal injury in mice.[17] However, the exact molecular mechanism of xenon-mediated neuroprotection remains to be elucidated. Moreover, the neuroprotective effect of xenon in WMD has not been adequately investigated.

MicroRNAs (miRNAs) are endogenous, non-coding small RNA molecules of about 22 nucleotides in length and are involved in regulating gene expression, primarily at the posttranscriptional level. MiRNAs play a ubiquitous role in many vital biological processes, such as cell differentiation, proliferation, and apoptosis, etc. miR-210 is recognized as one of the most stable and significant microRNAs, and it is a stable target gene of HIF-1α, during hypoxia, HIF-1α is up-regulated, which induces the expression of microRNA-210 to increase. [18] In this study, we investigated the neuroprotective effects of xenon in a neonatal rodent model of WMD. Further, we examined the impact of xenon on the outcome through measuring the expression of HIF-1α and miR-210 in neonatal brains.

Methods

Animals and Experimental groups

Experiments were performed with 120 SD rat pups (the Experimental Animal Center of Qingdao, China), postnatal days 3 (P3) rat pups, weighing 7.5–11.3g, housed in temperature- and humidity-controlled cages with their moms. Light was maintained in a 12-h light/dark cycle. All protocols were approved by the Institutional Animal Care and Use Committee of Qingdao University. All measures were taken to minimize animal discomfort.

Pups were randomly assigned into 3 different groups: sham-operated group (Group A, n=24), LPS + HI group (Group B, n=24), and LPS + HI + Xe (n=72). According to the onset of xenon treatment, the LPS + HI + Xe group was further divided into three subgroups, Group C (n=24), Group D (n=24) and Group E (n=24). which are separately delayed 0 hour, 2 hours, and 5 hours after HI.

Induction of WMD and Xenon treatment

Rat pups in Group B and Group C were first injected intraperitoneally (Ip) with LPS (Escherichia coli 0111:B4; Sigma, USA), while the Sham-operated pups (Group A) injected with normal saline (NS). To avoid LPS-induced body temperature changes, the rat pups were returned to their dams after LPS or NS injection, and housed in an incubator to maintain body temperature at 33 to 34°C before HI for 3 hours [19]. Next, pups were anesthetized with 5% chloral hydrate (0.01 ml/gm body weight, i.p) and HI was induced as described previously.[20]. Briefly the right common carotid artery (CCA) was exposed, separated from nerves and veins and permanently ligated with 4-0 surgical silk. After the wound was sutured, the pups were allowed to return to the cages and recover from anesthesia. The entire surgical procedure never exceeded 5 minutes. Sham-operated pups underwent the same operative procedure except that the exposed carotid artery was not ligated. After surgery, the pups were returned to the cages. After 1-hour recovery, pups in Group B and Group C, D, E were placed in an airtight 3 L container partially submerged in a 36°C water bath, and exposed to humidify 8% oxygen (a mixture of 8% O2 and 92% N2)
with a flow rate of 3 L/minute for 1 hour. Following hypoxia, pups in Group B were returned to the cage until they were sacrificed. Group C, Group D, Group E were separately placed in a closed circuit container within 50% xenon (mixed with 30% oxygen and 20% nitrogen) for 3 hours[21]. The start of the 3 hours of xenon-treatment in Group C, Group D and Group E was separately delayed 0 hour, 2 hours, and 5 hours after HI. Carbon dioxide was removed from the container by soda lime pellets. The decapitation of rats was begun 0 hour, 24 hour, 48 hours and 72 hours after xenon treatment, and the rats in Group A and Group B were also decapitated at the same time with Group C. Animals were allowed to survive 3 days, 4 days, 5 days and 6 days.

**Hematoxylin and eosin staining**

Brains were excised as described previously. [22] Briefly, pups were anesthetized with chloral hydrate and fixed on an operating panel. Next, the heart was exposed and a 10 ml syringe with 4% paraformaldehyde was inserted from the left ventricle to the aorta. Paraformaldehyde was injected into the heart until clear liquid flowed out from the atrium and the extremities became pale and stiff. Subsequently, the skull was systematically stripped to expose cerebral tissue. The periventricular brain tissue was dissected, immediately placed in 4% paraformaldehyde solution at room temperature for 48 hours, dehydrated in ethanol series, and embedded in paraffin. Paraffin blocks were coronally sectioned at a 10-μm thickness from the genu of the corpus callosum to the end of the dorsal hippocampus. Hematoxylin and eosin (HE) staining was performed in four sections per brain. Stained sections were observed under a light microscope (OLYMPUS BX41, Olympus, Center Valley, PA, USA).

**TUNEL staining**

Apoptosis was detected with terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling assay (TUNEL, Roche) according to the manufacturer’s protocol. Cells showing brown nuclei were considered as TUNEL positive cells and the average number of TUNEL positive cells from 5 randomly selected areas was counted under a light microscope (OLYMPUS BX41, Olympus, Center Valley, PA, USA).

**Western blot analysis**

Brain tissues were stored in aliquots at -80°C until needed for further analysis. Western blotting was carried out to detect the levels of HIF-1α in the white matter. The Brain tissue samples were homogenized in cold lysis buffer and the protein concentrations were determined using a BCA Protein Assay kit (Elabscience, Wuhan, China). Samples (40μg) were separated using 10% SDS-PAGE and blotted onto polyvinylidene fluoride membranes overnight at 4°C. The membranes were incubated with primary antibodies including anti-HIF-1α (1:500; Elabscience, Wuhan, China), and anti-GAPDH (1:1,000; Elabscience, Wuhan, China). After incubation, membranes were washed 5 times for 3 minutes. Proteins were visualized using anti-rabbit IgG antibodies which were conjugated to horseradish peroxidase (HRP) (1:50,000;Elabscience, Wuhan, China). Immunoreactivity was detected by horseradish-conjugated secondary antibodies and visualized by enhanced chemiluminescence. The band signals were quantified using an imaging software (BandScan 5.0).
Real-Time Reverse Transcription–PCR

Total RNA was extracted from brain tissue using Trizol (Aidlab, Lot:252250AX, Beijing, China) followed by quantification and reverse transcription using HiScript Reverse Transcriptase (RNase H) reagent Kit (Gene Copoeia®, MD, USA) following the standard protocols. Next, real-time PCR was performed using the 2× All-in-one qPCR Mix Kit (Vazyme Biotech, Nanjing, China). Then used specific miR-210 and an endogenous control U6 stem-loop primer, miR-210 or U6 stem-loop reverse transcriptase primers in a 20µl system buffered with RT buffer and Distilled De-ionized Water (ddH2O). The RT thermal cycle program was as follows: 25°C for 5 mins, 50°C for 15 mins, 85°C for 5 mins and 4°C 10 mins. The resulting cDNA was stored at -20°C. qPCR reaction (40 cycles) at 50°C for 2 mins, at 95°C for 10 mins, at 95°C 30 s, and at 60°C for 30 s. After amplification, the relative gene expressions were calculated in accordance with the ΔΔCt method. Relative miRNA levels were expressed as $2^{-\Delta\Delta\text{Ct}}$ and ratios to control. Samples were analyzed in triplicates and the data from 6 RT-PCR samples were averaged.

Statistical analysis

All data were expressed as mean ± SE. Statistical analysis was performed using IBM SPSS Statistics. The data conformed to normal distribution ($P > 0.05$), and met the homogeneity of variance ($P > 0.05$). Variance analysis was used and LSD was used to compare the two. Data didn’t conform to normal distribution ($P < 0.05$), or to normal distribution but didn’t meet the homogeneity of variance, non-parametric test was used and two comparisons were made, $p < 0.05$ was considered statistically significant.

Results

Protective effect of xenon following LPS and HI injury

First, we examined the efficiency of LPS and HI in inducing WMD in P3 rat pups. In Group A (sham-operated), HE staining of brain tissue demonstrated a normal white matter structure and morphology, regular cell arrangement and a clear endoblast at 0, 24, 48 and 72 hours (Fig.1 A-D, respectively). Upon the induction of WMD, in Group B, regular cell arrangement almost disappeared, along with structure loosen, cellular swelling, nuclear membranes were unclear, cell nucleis showed pyknosis, and necrosis were detected (Fig.1E-H). The abnormal structure and morphology observed in the white matter following LPS and HI indicate that LPS-sensitized HI-induced WMD in group B pups. Following the 3-hour xenon inhalation, the pathological changes induced by LPS and HI were less prominent in group C compared to group B supporting the notion that xenon could protect against brain injury in premature rats at 0, 24, 48 and 72 hours (Fig1 I-L, respectively).

Xenon alleviated the LPS and HI-induced apoptosis

Next, we performed TUNEL staining to estimate the apoptosis at 24, 48 and 72 hours following LPS and HI treatment. In the sham-operated group (group A), TUNEL staining did not reveal significant apoptosis.
In contrast, pups in group B showed a significant increase in apoptotic cells in the white matter at all examined time points (Fig.2 A-C). Further, the apoptosis rate was directly correlated with the survival period, i.e. the number of apoptotic cells significantly increased at 48h and peaked at 72 h following LPS and HI insult (Fig.2 G). Following xenon treatment in group C, the number of apoptotic cells significantly decreased at different time points compared to group B which is Xenon untreated (P<0.05 at 24, 48 and 72 hours, respectively.Fig.2 D-F and G).

**Xenon up-regulated the expression of miR-210 following white matter injury**

To investigate the effect of xenon treatment on the WMD, we detected the miR-210 level by RT-PCR. Compared to in group A, the expression level of miR-210 in neonatal rats' periventricular tissue increased significantly at all time points in group B (p<0.05). While the expression level of miR-210 in brain tissues of group B was significantly lower at 48h and 72h than that of group C (p<0.05), but made no difference with that of group D or group E (p>0.05). Compared with group C, the expression of miR-210 in brain tissues of group D decreased significantly at 24h and 72h (p<0.05), and group E decreased significantly at 0h,24h,48h and 72h (p<0.05). In addition, the expression of miR-210 at each group increased firstly and then decreased, and reached the peak at 48 hours. (Table 1 and Fig.3)

**Xenon up-regulated the expression of HIF-1α after white matter injury**

Next, we investigated the expression of HIF-1α and the efficiency of xenon treatment. Compared to in group A, Detection of HIF-1α protein by Western blot, The expression level of HIF-1α protein increased firstly and then decreased in each group, reaching peak at 24h, and was statistically differentiated with each other at every time point (p<0.05). The level of HIF-1α protein in group B brain tissues was significantly higher than that of group A at each time point, while significantly lower than that of group C and D and E at 0h,24h and 72h (p<0.05). Compared with group C and group D, the expression of HIF-1α in the brain tissue of group E decreased significantly at 24h (p<0.05). (Table 2 and Fig.4)

**Discussion**

The complex pathophysiology of WMD enables multiple targets at different time points of the disease process. For instance, therapies are mainly concentrated on reduction of excitotoxic, oxidative and apoptotic mediators of injury in the early phase. Because of the severity of disability that may result, the development of therapies is important to reduce brain injury secondary to WMD.

HIF-1α is an important factor in the regulation of hypoxia, and has been proved involved in hypoxic-ischemic preconditioning in multiple species of tissues as a transcription factor. Physiologically, HIF-1α is hydroxylated by prolyl-4-hydroxylases (PHDs) in the oxygen-dependent degradation domain of proline. After that, HIF-1α becomes ubiquitin ligase complex, which is degraded by proteasome. Under normoxic conditions, HIF-1α protein has a very short half-life (less than 5 min under posthypoxic conditions in cell culture), and decreases in oxygen concentration cause its stability to increase almost immediately, as reduction of PHD activity leading to degradation of proteasome. [23] HIF-1α targets a wide variety of
genes, including genes involved in energy metabolism, angiogenesis, cell proliferation, and survival. Among others, [24] and plays a role in hypoxic preconditioning in many organs by increasing the expression of HIF-1α, [25, 26] especially in the brain, HIF-1α plays an important role. Prass et al. [27] showed that hypoxia-induced HIF-1α DNA connectivity increased, leading to cerebral ischemic tolerance. Hypoxic stimulation up-regulates the expression of HIF-1α and EPO protein, produces reactive oxygen species, and plays an obvious neuroprotective role. [28] Recently, a number of microRNAs induced during hypoxia have been identified. Among these microRNAs, miR-210 is strongly induced by HIF-1α and has pleiotropic effects. [29] Fasanaro et al. reported that the expression level of miR-210 in endothelial cells was up-regulated in hypoxic environment, while promoting angiogenesis to a certain extent. [30] It is also closely related to hypoxic-ischemic diseases of the brain. Most studies have shown a direct link between the expression of miR-210 and hypoxia. [31-35] In particular, the expression of miR-210 was significantly up-regulated between normal and transformed cells, at the binding site of HIF-1α on its promoter. [34] Some studies have shown that miR-210 plays an important role in cell survival, during hypoxia as a highly up-regulated microRNA. [29,30] Under normoxic conditions, the presence of miR-210 is not effective, but when hypoxia occurs, the increase of miR-210 expression will reduce the effect of hypoxic environment on cell metabolism to a minimum. [36] MiR-210 is a stable target of HIF-1α, which induces the up-regulation of the expression of miR-210 under hypoxic environment. [17] Hypoxia can promote the expression of HIF-1α increasing at 4 hours, peaking at 8 hours and decreasing at 24 hours, and apoptosis increases significantly at 24 hours after hypoxia, accompanied by down-regulation of HIF-1α expression, that suggesting HIF-1α may play a protective role in regulating apoptosis. [37] Animal experiments and cell culture data showed that the level of miR-210 increased immediately after hypoxic injury, and then decreased for several days. Along with ischemia and hypoxia, the level of HIF-1α also changed continuously. Therefore, the level of miR-210 increasing after HI injury was regulated by HIF-1α and related to the time of injury. [29,38] Kelly [39] recently discovered the loop of miR-210 regulating HIF-1α and identified a new HIF-1α regulatory factor, glycerol-3-phosphate dehydrogenase 1-like (GPD1L). The induction of miR-210 by HIF-1α reduced the expression of GPD1L protein, thereby increasing the stability of HIF-1α. In conclusion, HIF-1α protein increased significantly in a certain period, peaked at 24 hours, and then gradually decreased to baseline level with the extension of time after HI injury in neonate rats. The protective effect was enhanced and then weakened. If intervention treatment was given after HI, HIF-1α degradation was inhibited to protect brain tissue, and the expression of miR-210 is related to the level of HIF-1α protein, that will bring new ideas for the follow-up treatment of neonatal brain damage. Our data suggest that the expression levels of HIF-1α protein and miR-210 in brain tissue increased after LPS combined with HI injury (p<0.05), which is consistent with the above study.

Xenon is an NMDA receptor antagonist that has been precluded from the widespread clinical use as a general anesthetic due to its relatively high cost. [14,15,40] Xenon has well documented neuroprotective properties that were reported in models of premature brain injury, [7,10,11,40] as shown in our previous papers. [41] In this study, we investigated the acute neuroprotective outcomes of xenon in an in vivo model of premature brain injury. In accordance with previous reports, we opted to use a 3-hour xenon treatment interval. [21,42] The present results indicate that xenon has the greatest neuroprotective effect in the
range of 37.5-50 vol%, which is consistent with previous studies that 50% xenon can provide sufficient neuroprotective effect.[43-45] On the contrary, others have shown that xenon at 75% volume concentration has the greatest neuroprotective effect and does not affect oxygenation[43]. However, in addition to neuroprotective effect, xenon at this concentration may have adverse side effects.[45] We choose a mixture of 50% xenon, 30% oxygen and 20% nitrogen to intervene, the mixture has 2.8× the density but almost the same viscosity as air.[46] In our study, following LPS and HI insult, we observed the expression of miR-210 and HIF-1α elevated, and our results revealed that the administration of 50% xenon balanced with 30% oxygen and 20% nitrogen for 3 hours after injury resulted in a significant increase of miR-210 and HIF-1α (p<0.05). These results suggest that xenon can alleviate white matter damage by activating HIF-1α expression, and the stable expression of HIF-1α can regulate the expression of microRNA-210, which plays a neuroprotective role by inhibiting neuronal apoptosis through related pathways. The available time-window for treatment effectiveness and administration is an important aspect to consider in potential treatments for premature brain injury. Therefore, we investigated the effectiveness of xenon when administered immediately or delayed for 2 or 5 hours following LPS and HI-induced injury. The level of microRNA-210 did not increase significantly, but the level of HIF-1α protein did not decrease significantly. Maintaining and stabilizing the level of HIF-1α protein still served to protect brain tissue. In addition, results revealed that the delay in xenon administration for 5 hours resulted in a significant increase of HIF-1α (p>0.05), which may suggest that xenon still exerts its neuroprotective effects for up to 5 hours after injury, and the regulation between HIF-1α and microRNA-210 is related to the time of injury, and may suggest that xenon still exerts its neuroprotective effects for up to 5 hours after injury, the sooner the better.

In summary, we showed that xenon is an efficient neuroprotective agent against premature brain injury in a rodent model of WMD. Our results indicated that xenon treatment up regulated the expression of miR-210 and HIF-1α and improved neurological outcome after WMD. The therapeutic time-window of xenon extends for up to 5 hours. Our findings are in agreement with the previously demonstrated neuroprotective effects of xenon in HI injury.[7,41] The duration of xenon treatment was relatively short (3 hours) which might suggest that the extension of treatment time might result in better neuroprotection and a longer therapeutic time window. Our findings support the idea that xenon could provide a first-line treatment for white matter injury in premature infants. The development of xenon-closed circuit delivery system and advances in gas extraction technology will potentially lead to enhanced procedures of xenon dosing with reduced cost.[47] Further, xenon is a non-flammable gas that can be easily administered at the bedside. In conclusion, the present study revealed a novel effect of xenon in protection against premature brain injury. Future experimental studies and clinical trials would be valuable in providing further insights into xenon neuroprotective efficacy.

**Conclusions**

In conclusion, our data indicate that the expression of HIF-1α and miR-210 increased in periventricular tissues and Xe could relieve the white matter damage by up-regulating the expression of HIF-1α and its
target gene miR-210. The Xe therapeutic time window was within 5 hours after intervention, the sooner the better.

**Abbreviations**

BBB: blood-brain barrier; CCA: Common carotid artery; GPD1L: Glycerol-3-phosphate dehydrogenase 1-like; HE: Hematoxylin and eosin; HI: Hypoxia-ischemia; HIF-1α: hypoxia inducible factor 1α; LPS: lipopolysaccharide; miR-210: microRNA 210; miRNAs: MicroRNAs; NMDA: N-methyl-D-aspartate; PHDs: Prolyl-4-hydroxylases; WMD: White matter damage;

**Declarations**

**Ethics approval and consent to participate**

The protocols, which include all surgical procedures and animal usage, were approved by the Institutional Animal Care and Use Committee of Qingdao University, and conformed to the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health.

**Consent for publication**

Not applicable

**Availability of data and material**

The data and analysis in this study could be reasonably acquired from the corresponding author.

We use the same animals as a source of samples for the studies outlined in this manuscript (Impact of Xenon on CLIC4 and Bcl-2 Expression in Lipopolysaccharide and Hypoxia-Ischemia-Induced Periventricular White Matter Damage, DOI: 10.1159/000487220)

**Competing interests**

None declared

**Funding**

This study was funded by grants-in aid from Shandong medical and health science and technology development program “Study on the neuroprotective effect of xenon on hypoxic ischemic brain damage in neonatal rats”. The authors would also like to thank Dr. Hong Jiang for his guidance and technical support.

**Authors' contributions**
YXY, ZJX, JH had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept, design, and drafting of the article: YXY, ZJX, LXH. Acquisition, analysis, and interpretation of data: JJ, XHM, ZLL. All authors have read and approved the manuscript.

Acknowledgements

Not applicable.

References

1. Peterson BS, Vohr B, Staib LH, Cannistraci CJ, Dolberg A, Schneider KC et al. Regional brain volume abnormalities and long-term cognitive outcome in preterm infants. *Jama* 2000;284(15):1939-1947.
2. Hintz SR, Barnes PD, Bulas D, Slovis TL, Finer NN, Wrage LA et al. Neuroimaging and neurodevelopmental outcome in extremely preterm infants. *Pediatrics* 2015;135(1):e32-42.
3. Dammann O, Leviton A. Inflammation, brain damage and visual dysfunction in preterm infants. *Seminars in fetal & neonatal medicine* 2006;11(5):363-368.
4. Khwaja O, Volpe JJ. Pathogenesis of cerebral white matter injury of prematurity. *Archives of disease in childhood Fetal and neonatal edition* 2008;93(2):F153-161.
5. Liu W, Liu Y, Chen H, Liu K, Tao HY, Sun XJ. Xenon preconditioning: molecular mechanisms and biological effects. *Medical gas research* 2016;3(1):3.
6. Ma D, Hossain M, Pettet GK, Luo Y, Lim T, Akimov S, et al. Xenon preconditioning reduces brain damage from neonatal asphyxia in rats. *Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism* 2006;26(2):199-208.
7. Yang T, Zhuang L, Rei Fidalgo AM, Petrides E, Terrando N, Wu X, et al. Xenon and sevoflurane provide analgesia during labor and fetal brain protection in a perinatal rat model of hypoxia-ischemia. *PloS one* 2012;7(5):e37020.
8. Arola OJ, Laitio RM, Roine RO, Gronlund J, Saraste A, Pietila M, et al. Feasibility and cardiac safety of inhaled xenon in combination with therapeutic hypothermia following out-of-hospital cardiac arrest. *Critical care medicine* 2013;41(9):2116-2124.
9. Azzopardi D, Robertson NJ, Kapetanakis A, Griffiths J, Rennie JM, Mathieson SR, et al. Anticonvulsant effect of xenon on neonatal asphyxial seizures. *Archives of disease in childhood Fetal and neonatal edition* 2013;98(5):F437-439.
10. Sheng SP, Lei B, James ML, Lascola CD, Venkatraman TN, Jung JY, et al. Xenon neuroprotection in experimental stroke: interactions with hypothermia and intracerebral hemorrhage. *Anesthesiology* 2012;117(6):1262-1275.
11. Bickler PE, Warren DE, Clark JP, Gabatto P, Gregersen M, Brosnan H. Anesthetic protection of neurons injured by hypothermia and rewarming: roles of intracellular Ca2+ and excitotoxicity. *Anesthesiology* 2012;117(2):280-292.
12. Goto T, Nakata Y, Morita S. Will xenon be a stranger or a friend?: the cost, benefit, and future of xenon anesthesia. *Anesthesiology* 2003;98(1):1-2.

13. Rossaint R, Reyle-Hahn M, Schulte Am Esch J, Scholz J, Scherpereel P, Vallet B, et al. Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. *Anesthesiology* 2003;98(1):6-13.

14. Neukirchen M, Hipp J, Schaefer MS, Brandenburger T, Bauer I, Winterhalter M, et al. Cardiovascular stability and unchanged muscle sympathetic activity during xenon anaesthesia: role of norepinephrine uptake inhibition. *British journal of anaesthesia* 2012;109(6):887-896.

15. Armstrong SP, Banks PJ, McKitrick TJ, Geldart CH, Edge CJ, Babla R, et al. Identification of two mutations (F758W and F758Y) in the N-methyl-D-aspartate receptor glycine-binding site that selectively prevent competitive inhibition by xenon without affecting glycine binding. *Anesthesiology* 2012;117(1):38-47.

16. Dickinson R, Peterson BK, Banks P, Simillis C, Martin JC, Valenzuela CA, et al. Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor by the anesthetics xenon and isoflurane: evidence from molecular modeling and electrophysiology. *Anesthesiology* 2007;107(5):756-767.

17. Ma D, Lim T, Xu J, Tang H, Wan y, Zhao H, et al. Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation. *J Am Soc Nephrol* 2009; 20:713–20

18. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. *Clin Cancer Res* 2008,14(5): 1340-1348.

19. Wang LW, Chang YC, Chen SJ, Tseng CH, Tu YF, Liao NS, et al. TNFR1-JNK signaling is the shared pathway of neuroinflammation and neurovascular damage after LPS-sensitized hypoxic-ischemic injury in the immature brain. *Journal of neuroinflammation* 2014a; 11:215.

20. Back SA, Han BH, Luo NL, Chricton CA, Xanthoudakis S, Tam J, et al. Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2002;22(2):455-463.

21. David HN, Haelewyn B, Rouillon C, Lecoq M, Chazalviel L, Apiou G, et al. Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 2008;22(4):1275-1286.

22. Shibata M, Ohtani R, Ihara M, Tomimoto H. White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. *Stroke* 2004;35(11):2598-2603.

23. Rishi M, Selvaraju V, Thirunavukkarasu M, Shaikh IA, Takeda K, Fonq GH, et al. Deletion of prolyl hydroxylase domain proteins (PHD1, PHD3) stabilizes hypoxia inducible factor-1 alpha, promotes neovascularization, and improves perfusion in a murine model of hind-limb ischemia. *Microvascular research* 2015;97: 181-188.

24. Semenza, G. L. Targeting HIF-1 for cancer therapy. *Rev. Cancer* 2003;3:721–732.

25. Shizukuda Y, Mallet RT, Lee SC, Downey HF. Hypoxic preconditioning of ischaemic canine myocardium. *Cardiovasc Res* 1992;26:534-542.
26. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003;108(1): 79-85.

27. Prass K, Scharff A, Ruscher K, Lowl D, Muselmann C, Victorov I, et al. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 2003;34(8):1981-1986.

28. Liu J, Narasimhan P, Yu F, Chan PH. Neuroprotection by hypoxic preconditioning involves oxidative stress-mediated expression of hypoxia-inducible factor and erythropoietin. Stroke 2005; 36:1264-1269.

29. Kulshreshtha, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, et al. A microRNA signature of hypoxia. Mol. Cell. Biol 2007;27:1859–1867.

30. Fasanaro P, Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. Biol Chem 2008;283(23): 15878-83.

31. Le QT, Giaccia AJ. MiR-210—micromanagement of the hypoxia pathway. Trends Mol Med 2010;16:230-237.

32. Ivan M, Huang X. miR-210: fine-tuning the hypoxic response. Adv Exp Med Biol 2014;772:205-227.

33. Qin Q, Furong W, Baosheng L. Multiple functions of hypoxia-regulated miR-210 in cancer. J Exp Clin Cancer Res 2014;33:50.

34. Malm T., Turunen M, Koistinaho J, Yia-Herttuala S. Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett 2008;582:2397-2401.

35. Kim HW, Haider HK, Jiang S, Ashraf M. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem 2009;284: 33161-33168.

36. Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL, Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2[J]. Cell Metab 2009;10(4):273-284.

37. Li L, Qu Y, Li J, Xiong Y, Mao M, Mu D. Relationship between HIF-1alpha expression and neuronal apoptosis in neonatal rats with hypoxia-ischemia brain injury. Brain Res 2007;1180: 133-139.

38. Zeng L, Liu J, Wang Y, Wang L, Weng S, Tang Y, et al. MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia. Front Biosci (Elite Ed) 2011;3: 1265-1272.

39. Kelly TJ, Souza AL, Clish CB, Puiqserver P. A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell Biol 2011;31: 2696-2706.

40. Banks P, Franks NP, Dickinson R. Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor mediates xenon neuroprotection against hypoxia-ischemia. Anesthesiology 2010;112(3):614-622.
41. Xiangyun Yin, Jixiu Zhao, Hong Jiang, Liangliang Li, Jian Jiang, Hongmin Xi. Impact of Xenon on CLIC4 and Bcl-2 Expression in Lipopolysaccharide and Hypoxia-Ischemia-Induced Periventricular White Matter Damage. *Neonatology* 2018;113:339-346.

42. Campos-Pires R, Armstrong SP, Sebastiani A, Luh C, Gruss M, Radyushkin K et al. Xenon improves neurologic outcome and reduces secondary injury following trauma in an in vivo model of traumatic brain injury. *Critical care medicine* 2015;43(1):149-158.

43. Ma D, Hossain M, Chow A, Ashad M, Battson RM, Sanders RD, et al. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. *Annals of neurology* 2005;58,(2):182-193.

44. Dingley J, Tooley J, Porter H, Thoresen M. Xenon provides short-term neuroprotection in neonatal rats when administered after hypoxia-ischemia. *Stroke* 2006;37:501-506.

45. Abraini J H, David HN, Lemaire M. Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon. *Ann N Y Acad Sci* 2005;1053: 289-300.

46. Jaffrin MY, Kesic P. Airway resistance: a fluid mechanical approach. *Appl Physiol* 1974;36: 354-361.

47. Faulkner SD, Downie NA, Mercer CJ, Kerr SA, Sanders RD, Robertson NJ. A xenon recirculating ventilator for the newborn piglet: developing clinical applications of xenon for neonates. *European journal of anaesthesiology* 2012;29(12):577-585.

### Tables

Table 1. Expression of miR-210 (as means ± SE) in the brain tissue at different time points in group A-E

| Time | Group A     | Group B     | Group C     | Group D     | Group E     | F       | P       |
|------|-------------|-------------|-------------|-------------|-------------|---------|---------|
| 0 h  | 1.1777±0.1033 | 2.1105±0.7881 | 3.2123±0.8098 | 2.1400±0.2077 | 1.5578±0.3774 | 12.044  | 0.000   |
| 24 h | 1.2943±0.2501 | 2.7547±0.8061 | 3.5862±0.6991 | 2.4792±1.2063 | 1.8092±0.4965 | 8.035   | 0.000   |
| 48 h | 1.2943±0.2501 | 3.6247±1.1523 | 7.3270±2.1808* | 3.7732±2.7645 | 2.2940±1.2560 | 10.212  | 0.000   |
| 72 h | 1.1777±0.1033 | 1.9407±0.5469 | 2.6175±0.1898* | 1.7612±0.9202 | 1.9000±0.3614 | 5.982   | 0.002   |
Table 2. The expression of HIF-1α (as means ± SE) in the brain tissue at different time points in groups A - E

| Time  | Group A          | Group B          | Group C          | Group D          | Group E          | F      | p       |
|-------|------------------|------------------|------------------|------------------|------------------|--------|---------|
| 0h    | 0.2273±0.0689    | 0.3435±0.0165*   | 0.4578±0.0492▲   | 0.4428±0.0434▲   | 0.4225±0.0328▲   | 26.292 | 0.000   |
| 24h   | 0.2448±0.0430    | 0.5173±0.0325*   | 0.6582±0.0351▲   | 0.6167±0.0364▲   | 0.5667±0.037▲    | 95.551 | 0.000   |
| 48h   | 0.2557±0.0754    | 0.4175±0.0559*   | 0.5080±0.0709    | 0.4597±0.0592    | 0.4747±0.0313    |        |         |
| 72h   | 0.2617±0.0338    | 0.3745±0.0225*   | 0.4330±0.0373▲   | 0.4273±0.0202▲   | 0.4297±0.0160▲   | 43.334 | 0.000   |

Figures

Figure 1

Representative hematoxylin and eosin-stained coronal brain sections from postnatal day 3 SD rat pups. (A-D) a normal white matter structure and morphology, regular cell arrangement in the sham-operated pups (group A) at 0, 24, 48 and 72 hours, respectively (n=6). (E-H) Distorted cytoarchitecture, nuclear psychosis (white arrows), and cellular swelling (black arrows) observed in the brain sections following LPS and HI in group B at 48 and 72 hours, (n=6). (I-L) Protective effect of xenon in group C pups at 0, 24, 48 and 72 hours, (n=6). Scale bar=50 μm in B-D, F, H-L; Scale bar=100 μm in A, E and G.

Figure 2

Representative images of TUNEL staining from postnatal day 3 SD rat pups. (A-C) Following LPS and HI the number of apoptotic cells increased significantly in group B pups at 24, 48 and 72 hours (n=3). (D-F) Protective effect of xenon in group C pups at 24, 48 and 72 hours, (n=3). Bar chart representing the average number of TUNEL positive cells of group B and group C, *p<0.05 compared to group B.
Figure 3

Expression of miR-210 in the brain tissue at different time points in group A-E. A: Bar charts representing the relative expression of miR-210 at 0, 24, 48 and 72 hours in group A and B, # p<0.05 compared to group A (n=6). B: Bar charts representing the relative expression of miR-210 in groups B, C, D and E at 0, 24, 48 and 72 hours. * p<0.05 compared to group B (n=6), △ p<0.05 compared to group C (n=6)

Figure 4
The expression of HIF-1α in the brain tissue at different time points in groups A-E. A Western blot analysis of HIF-1α expression at 0 h among the different groups, and bar chart representing the quantitative analysis of HIF-1α expression level normalized to GAPDH level, # p < 0.05 compared to group A, ▲ p < 0.05 compared to group B (n = 6). B Western blot analysis of HIF-1α expression among the different groups at 24 h, and bar chart representing the quantitative analysis of HIF-1α expression level normalized to GAPDH level, # p < 0.05 compared to group A ▲ p < 0.05 compared to group B, * p < 0.05 compared to group C, △ p < 0.05 compared to group D (n = 6). C HIF-1α expression among the different groups at 48 h, and bar chart representing the quantitative analysis of HIF-1α expression level normalized to GAPDH level, # p < 0.05 compared to group A, ▲ p < 0.05 compared to group B (n = 6). D HIF-1α expression among the different groups at 72 h, and bar chart representing the quantitative analysis of HIF-1α expression level normalized to GAPDH level, # p < 0.05 compared to group A, ▲ p < 0.05 compared to group B (n = 6).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- NC3RsARRIVEGuidelinesChecklist2014.docx